Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

March 3rd, 2014

First ten patients enrolled in U.S. clinical study that is evaluating treatment of iliofemoral venous outflow obstruction

Bloomington, Ind.— The first ten patients have been enrolled in Cook Medical’s VIVO clinical research study. The study is designed to evaluate the safety and effectiveness of treating symptomatic iliofemoral venous outflow obstruction with the Zilver® Vena™ Venous Self-Expanding Stent. The trial’s first patients are undergoing treatment at six healthcare facilities in the East Coast and Midwest regions. Dr. Charles B. Ross, chief of vascular and endovascular services at Piedmont Heart Institute was the first physician to enroll a patient in the study.

“I am overjoyed to be part of a trial specifically designed to address iliofemoral venous outflow obstruction with a stent designed for this purpose,” said Dr. Ross. “With the Zilver Vena stent and VIVO trial, we enter a new and exciting era. I feel privileged to participate.” “Cook sees this as an important step in the battle against iliofemoral venous outflow obstruction,” explained Mark Breedlove, vice president and global leader of Cook’s Peripheral Intervention clinical division. “By conducting the VIVO clinical research study, we hope to advance our understanding of venous disease while providing new treatment options for patients.”

For more information, please visit  The Zilver Vena Venous Self-Expanding Stent is an investigational device that is not approved for sale in the United States.

About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family-owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at, and for the latest news, follow us on TwitterFacebook and LinkedIn.